| |
(Scroll Down for BI-07 References)
REFERENCES
Scientific and Clinical Studies
Theralac® Probiotic Strains
Bifidobacterium lactis strain BL-34 (Also called Bl-04) present in Theralac® at 10 Billion CFU per Capsule
References:
Human strain on deposit at the American Type Culture
Collection (ATCC) as SD5219
Ventura, V. and Zink, R. (2002). Rapid identification,
differentiation, and proposed new taxonomic classification of Bifidobacterium lactis. Appl. Environ.
Microbiol. 68(12):6429-6434.
B. lactis is on the EU Safety
List for Human consumption: www.efsa.europa.eu/ESFA/Scientific_Opinion/sc_op_ej587_qps_en.pdf
Borriello,
S.P., Hammes, W.P., Holzapfel, W., Marteau, J., Schrezenmeir, J., Vaara, M. and
Valtonen, V. (2003). Safety of Probiotics That Contain Lactobacilli or
Bifidobacteria. Clinical Infect. Disease 36:775-780.
Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders, M.E.,
Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to minimize the
disruption of faecal microbiotia in healthy subjects undergoing antibiotic
therapy. J. Medical Microbiology 58:663-670.
Bartosch, S., Woodmansey, E.J., Paterson, J.C.M., McMurdo,
M.E.T. and Macfarlane, G.T. (2005). Microbiological effects of consuming a
symbiotic containing Bifidobacterium
bifidum, bifidobacterium lactis, and oligofructose in elderly persons,
determined by real-time polymerase chain reaction and counting of viable
bacteria. Clinical Infect. Diseases. 40:28-37.
Foligne, B., Nutten, S., Grangette, C., Dennin, V.,
Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot,
B. (2007). Correlation between in vitro and
in vivo immunomodulatory properties
of lactic acid bacteria. World J. Gastroenterology 13(2):236-243.
Lammers, K.M., Brigidi, P., Vitali, B., Gionchetti, P.,
Rizello, F., Caramelli, E., Matteuzzi, D. and Campieri, M. (2003).
Immunomodulatory effects of probiotic bacteria DNA:IL-1 and IL-10 response in
human peripheral blood mononuclear cells. FEMS Immunology and Medical
Microbiology 38:165-172.
Bifidobacterium lactis strain Bi-07 present in Theralac® at 3 Billion CFU Per Capsule
References:
Complimentary human strain synergistic with BL-34 on deposit
at the American Type Culture Collection (ATCC) as SD5220
Engelbrektson, A., Korzenik, J.R., Pittler, A., Sanders,
M.E., Klaenhammer, T.R., Leyer, G. and Kitts, C.L. (2009). Probiotics to
minimize the disruption of faecal microbiotia in healthy subjects undergoing
antibiotic therapy. J. Medical Microbiology 58:663-670.
Ventura,
V. and Zink, R. (2002). Rapid identification, differentiation, and proposed new
taxonomic classification of Bifidobacterium
lactis. Appl. Environ. Microbiol. 68(12):6429-6434.
Foligne, B., Nutten, S., Grangette, C., Dennin, V.,
Goudercourt, D., Poiret, S., Dewulf, J., Brassart, D., Mercenier, A. and Pot,
B. (2007). Correlation between in vitro and
in vivo immunomodulatory properties
of lactic acid bacteria. World J. Gastroenterology 13(2):236-243.
Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Farmer,
J., Roberts, L., Hilty, M. and Balish, E. (1997). Biotherapeutic effects of
probiotic bacteria on candidiasis in immunodeficient mice. Infect. Immun.
65:4165-4172.
Ruiz-Palacios, G.F., Guerrero, M., Hilty, M., Dohnalek, P., Newton, P., Calva, J.J.,
Tostigan, T., Tuz, F. and Arteaga, M.L. (1999). Feeding of a probiotic for the
prevention of community acquired diarrhea in young Mexican children. Pediatr.
Res. 39(2):104 (abstr).
Provisional Patent Application. Ser. No. 60/848,662 filed on
2 October 2006.
|